“It’s not as bad as it was.” There are sentences in medicine that sound reassuring until you stay with them for another minute. The hives are less frequent. Antihistamine is doing something. Maybe the patient is sleeping better than they were six months ago, or calling the office less, or no longer waking every morning wondering what their skin will look like by noon.

Progress, certainly. And yet, when you keep asking, another version of the story appears. “I still get hives, but I can deal with them,” or “Mostly at night,” or “Only a few times a week.”

By then, patients may have become remarkably skilled at accommodation. Loose clothing, different linens, a cooler bedroom, social plans made with a mental exit route. Scratching resisted until it cannot be. Sleep interrupted and then counted as normal because it has been interrupted for so long.

These are some of the daily difficulties of chronic spontaneous urticaria (CSU), a disease that can occupy a surprising amount of life without announcing itself every hour. We know how to recognize wheals and angioedema, but it is harder to see the space disease has taken up around those symptoms.

By one estimate, nearly 40% of patients with CSU report that the disease has a very large or extremely large impact on their quality of life, reflected in Dermatology Life Quality Index (DLQI) scores above 10.¹ Yet the patient sitting in front of us may not call it severe—just, better.

For the PA or NP who sees that patient repeatedly, this is where familiarity can become useful rather than blinding. You remember how they were doing three months ago, hear the small changes in language, and can ask specific questions that reveal more about the quality of life.

Are you still waking up itching? Do the hives change what you wear? Have you stopped exercising because you worry a flare will start? Are you still planning your day around the possibility of a flare?

The therapeutic landscape has now widened enough that residual disease deserves heightened attention. For patients who remain symptomatic despite H₁-antihistamines, current international guidance asks clinicians to think in terms of disease control rather than simple treatment exposure, assessing it with validated tools such as the Urticaria Control Test and the weekly Urticaria Activity Score (UAS7), and escalating care when control remains out of reach.²

Targeted options for antihistamine-refractory CSU now extend beyond the anti-IgE antibody omalizumab¹ to include the anti–IL-4Rα antibody dupilumab⁶ and, most recently, Bruton tyrosine kinase (BTK) inhibition. Remibrutinib, an oral BTK inhibitor, was approved by the FDA in September 2025 for adults with CSU who remain symptomatic despite H₁-antihistamine treatment.³

Its phase 3 REMIX-1 and REMIX-2 trials enrolled patients who remained symptomatic despite second-generation H₁ -antihistamines. At week 12, remibrutinib produced significantly greater reductions in UAS7 than placebo; more patients achieved well-controlled disease (UAS7 ≤6), and more reached complete response (UAS7 = 0). Improvements were sustained through the end of the 24-week placebo-controlled period.⁴ During a subsequent 28-week open-label treatment period, improvements in disease activity were maintained through week 52.⁵

Perhaps one of the more immediate consequences of those data is that they sharpen an older question: How much disease are we willing to leave behind? Not every breakthrough hive demands escalation, nor does every patient want the same thing from treatment. The existence of another option does, however, make “good enough” worth examining.

Maybe they are comfortable with occasional symptoms. Maybe they are not, but no one has asked lately. Maybe the itch has receded enough that sleep feels possible again, while the unpredictability of the disease still governs everything from clothing to travel. Maybe what mattered six months ago was simply getting through the night, and now they are ready to talk about control.

This is where shared decision-making becomes, more than anything, a habit of attention. What are you still living around? What would meaningful control look like to you? What do you want to know before changing treatment?

With oral targeted therapy now part of the CSU landscape, those conversations can include route of administration, expected response, safety considerations, and follow-up, alongside the things patients have always cared about: Will the itching stop or the hives come back? Can I sleep? Will I ever be able to stop thinking about this?

There is something almost paradoxical about chronic disease. The longer patients live with it, the better they may become at making it disappear from the story they tell us. Which is why, sometimes, the clearest sign that CSU is still in control is not the flare itself. It is everything the patient has learned to arrange around it.

.

.

References:

1. Kolkhir P, Bonnekoh H, Metz M, Maurer M. Chronic spontaneous urticaria: a review. JAMA. 2024;332(17):1464-1477. doi:10.1001/jama.2024.15568

2. Zuberbier T, Ansari ZAH, Abdul Latiff AH, et al. The international guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2026;81(8):2582-2632. doi:10.1111/all.70210

3. Rhapsido. Prescribing information. Novartis Pharmaceuticals Corp; 2025. Accessed September 10, 2026.

4. Metz M, Giménez-Arnau A, Hide M, et al; REMIX-1 and REMIX-2 Investigators. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984-994. doi:10.1056/NEJMoa2408792

5. Giménez-Arnau AM, Szalewski R, Hide M, et al. Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies. J Allergy Clin Immunol. 2026;157(1):143-154. doi:10.1016/j.jaci.2025.09.028

6. Dupixent. Prescribing information. Regeneron Pharmaceuticals Inc/Sanofi-Aventis US LLC; 2026. Accessed September 14, 2026.